**Core Concept**
Chloroquine-resistant falciparum malaria requires an alternative antimalarial agent to treat the infection effectively. This situation highlights the importance of resistance patterns in malaria parasites and the need for specific treatment strategies.

**Why the Correct Answer is Right**
The correct answer is Artemisinin-based Combination Therapy (ACT). Artemisinin is a potent antimalarial agent that works by generating free radicals, which damage the parasite's cell membrane and ultimately lead to its death. When used in combination with other antimalarials like lumefantrine, mefloquine, or sulfadoxine-pyrimethamine, ACTs enhance efficacy, reduce resistance development, and improve patient outcomes. The World Health Organization (WHO) recommends ACTs as the first-line treatment for uncomplicated falciparum malaria.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because it does not specify an Artemisinin-based Combination Therapy, which is the current standard of care for chloroquine-resistant falciparum malaria.
* **Option B:** This option is incorrect because it does not address the issue of chloroquine resistance, which necessitates a change in treatment.
* **Option C:** This option is incorrect because it is an outdated treatment regimen that may not be effective against chloroquine-resistant parasites.

**Clinical Pearl / High-Yield Fact**
Artemisinin-based Combination Therapies (ACTs) have revolutionized the treatment of falciparum malaria, reducing mortality rates and improving patient outcomes. However, their widespread use has raised concerns about resistance development, emphasizing the need for responsible antimalarial use and ongoing surveillance.

**Correct Answer:** C. Artemether-lumefantrine.